Preliminary program



List of topics/subtopics includes (but not exclusively):


Tumor biology: an ever-changing state-of-the-art and the necessity of merging quite different research fields

  • Tumor suppressor genes and tumor phenotype
  • Epigenetic control of cell and tissue fate are a continuum
  • Cell-autonomous and non-autonomous defence mechanisms against oncogene mutation and phenotypic tumor transformation
  • Exiting from the cell: aberrant homeostasis of cancer microenvironment in cancer genesis , progression and spreading
  • Injured tissue homeostasis is differntly controlled by DNA damage response in healty and tumor tissues: loss of apoptosis competence in cancer
  • Apoptosis, Caspases and regeneration in injured normal and cancer tissues: a concern in anticancer therapies
  • Microenvironment vs. oncogene mutations as the driving force in tumor genesis and progression: cancer phenotype and oncogene mutations are recessive traits


Biomodulatory approaches and communicative reprogramming in clinical anticancer therapies: Anakoinosis

  • Acute myelocytic leukemia: induction of anakoinosis
  • Chronic myelocytic leukemia/Langerhans cell histiocytosis: the role of pioglitazone
  • How to overcome poor risk molecular-genetic parameters in APL with Anakoinosis inducing therapy (ATRA plus ATO)
  • Classic targeted therapy combined with Anakoinosis inducing therapy
  • Metronomic chemotherapy: integrating the treatment concept
  • Metformin: how should we therapeutically proceed?
  • Transcriptional modulators in tumor therapy
  • Epigenetically modifying drugs and Anakoinosis inducing therapy
  • Epigenetic and differentiation therapy
  • Clinical achievements with communicative reprogramming in anticancer therapy
  • How to overcome the problem with undruggable targets
  • Addressing molecular-genetic tumor heterogeneity in metastatic disease
  • Modulatory drug combination: clinical achievements
  • Therapeutic modulation of tisue homeostasis in tumor microenvironment
  • Hepatocellular carcinoma and anakoinosis inducing therapy
  • PPARgamma agonists as universal effectors of cancer homeostasis normalization
  • Transcriptional modulators in tumor therapy

Anakoinosis and cancer care sustainability

  • Drug repurposing: concepts to integrate the idea in clinical strategies
  • Ever increasing costs of targeted anticancer therapies: biomodulatory therapies as a sustainable alternative
  • Development of pharmacological tools for producing efficacious and economically relevant biomodulatory drug cocktails

Anakoinosis, an ubiquitous phenomenon of systems biology

  • Communication between metastatic tumor and organ systems: example cachexia

Preclinical studies and experimental models to explore efficient anakoinosis drug combinations

  • Modulatory drug combination: translational studies
  • Targeting homeostatic systems: tumor suppressor genes and homeostatic pathways
  • Developing tools to study anakoinosis principles and improve its therapeutic efficacy (3D cultures, organ-on-chip, zebrafish)
  • Natural compounds as anakoinosis drugs: potentials, limits and prospective developments

Patronized by


Sponsors